See more : Altitude Acquisition Corp. (ALTU) Income Statement Analysis – Financial Results
Complete financial analysis of Pieris Pharmaceuticals, Inc. (PIRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Pieris Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shanghai Industrial Urban Development Group Limited (0563.HK) Income Statement Analysis – Financial Results
- Elektro Redes S.A. (EKTR4.SA) Income Statement Analysis – Financial Results
- Volkswagen AG (VWAGY) Income Statement Analysis – Financial Results
- Leef Brands Inc. (ICAN.CN) Income Statement Analysis – Financial Results
- NISSO HOLDINGS Co., Ltd (9332.T) Income Statement Analysis – Financial Results
Pieris Pharmaceuticals, Inc. (PIRS)
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases; PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis; and immune-oncology program comprises Cinrebafusp alfa, a 4-1BB/ HER2 bispecific for the treatment of HER2-high and HER2-low expressing gastric cancers. The company also develops PRS-344/S095012, a bispecific anticalin-antibody fusion protein targeting 4- 1BB and PD-L1 for immuno-oncology diseases that is in phase 1 clinical trial; and PRS-352, a preclinical-stage program addressing undisclosed targets for immuno-oncology diseases. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. The company also has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.81M | 25.90M | 31.42M | 29.32M | 46.28M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 9.88M | 11.38M |
| Cost of Revenue | 41.80M | 2.78M | 2.37M | 46.53M | 55.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.55M | 0.00 |
| Gross Profit | 1.01M | 23.12M | 29.05M | -17.21M | -8.72M | 29.10M | 25.28M | 5.83M | 2.93M | 5.37M | 12.43M | 11.38M |
| Gross Profit Ratio | 2.36% | 89.27% | 92.46% | -58.68% | -18.84% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 125.78% | 100.00% |
| Research & Development | 41.80M | 52.98M | 66.66M | 46.53M | 55.00M | 41.49M | 22.29M | 19.70M | 8.24M | 5.60M | 9.41M | 10.85M |
| General & Administrative | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.71M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 280.86K |
| SG&A | 16.85M | 16.39M | 16.59M | 16.71M | 18.44M | 18.44M | 17.58M | 8.89M | 8.37M | 6.96M | 2.46M | 2.99M |
| Other Expenses | 13.91M | -8.17M | -3.69M | -3.66M | -26.00K | 1.80M | -2.10M | 119.50K | 10.91K | 3.00K | 6.31K | 0.00 |
| Operating Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Cost & Expenses | 72.57M | 61.20M | 79.56M | 63.24M | 73.44M | 59.93M | 39.87M | 28.59M | 16.61M | 12.56M | 9.33M | 13.53M |
| Interest Income | 1.85M | 721.00K | 4.00K | 511.00K | 1.71M | 1.96M | 152.00K | 2.32K | 0.00 | 0.00 | 0.00 | 177.13K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.95M | 2.32K | 184.65K | 2.65M | 493.94K | 0.00 |
| Depreciation & Amortization | 1.78M | 2.78M | 2.37M | 2.13M | 1.04M | 570.00K | 369.00K | 361.38K | 307.91K | 366.98K | 384.68K | 378.32K |
| EBITDA | -22.76M | -30.50M | -43.37M | -31.61M | -26.12M | -30.26M | -14.23M | -22.40M | -13.37M | -6.83M | 938.50K | -1.80M |
| EBITDA Ratio | -53.17% | -136.29% | -153.24% | -108.43% | -56.43% | -103.99% | -56.28% | -390.33% | -466.25% | -134.11% | 9.56% | -15.83% |
| Operating Income | -29.76M | -43.47M | -51.83M | -33.92M | -27.16M | -30.83M | -14.59M | -22.76M | -13.68M | -7.20M | 553.83K | -2.18M |
| Operating Income Ratio | -69.51% | -167.84% | -164.97% | -115.68% | -58.68% | -105.94% | -57.74% | -390.33% | -466.62% | -134.17% | 5.61% | -19.15% |
| Total Other Income/Expenses | 5.21M | 10.20M | 6.09M | -3.15M | 1.69M | 3.77M | -1.95M | 122.00K | -173.74K | -2.65M | -487.63K | -140.55K |
| Income Before Tax | -24.54M | -33.28M | -45.74M | -37.07M | -25.47M | -27.07M | -16.54M | -22.64M | -13.85M | -9.85M | 66.20K | -2.32M |
| Income Before Tax Ratio | -57.33% | -128.47% | -145.58% | -126.41% | -55.03% | -93.01% | -65.46% | -388.24% | -472.55% | -183.60% | 0.67% | -20.39% |
| Income Tax Expense | 0.00 | -2.02M | -2.37M | 164.00K | -1.71M | -312.00K | 1.10M | 161.97K | 203.87K | -18.00 | 487.63K | 22.00 |
| Net Income | -24.54M | -31.25M | -43.37M | -37.23M | -23.76M | -26.75M | -17.65M | -22.80M | -14.06M | -9.85M | 66.20K | -2.32M |
| Net Income Ratio | -57.33% | -120.66% | -138.03% | -126.97% | -51.33% | -91.93% | -69.82% | -391.02% | -479.50% | -183.59% | 0.67% | -20.39% |
| EPS | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| EPS Diluted | -21.80 | -33.71 | -53.75 | -54.67 | -37.54 | -40.32 | -32.14 | -43.73 | -32.70 | -20.62 | 0.45 | -38.68 |
| Weighted Avg Shares Out | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
| Weighted Avg Shares Out (Dil) | 1.13M | 927.15K | 806.84K | 681.01K | 632.81K | 663.51K | 549.14K | 521.41K | 429.91K | 477.68K | 477.68K | 59.99K |
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
Pieris Pharmaceuticals, Inc. (PIRS) Q4 2022 Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals To Present at Evercore ISI Healthconx Conference
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Call Transcript
Pieris Pharmaceuticals To Host Third Quarter 2022 Investor Call and Provide Corporate Update on November 2, 2022
Pieris Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
Pieris Pharmaceuticals, Inc. (PIRS) CEO Steve Yoder on Q2 2022 Results - Earnings Call Transcript
Pieris Pharmaceuticals (PIRS) Reports Q2 Loss, Lags Revenue Estimates
Source: https://incomestatements.info
Category: Stock Reports